Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about UCB
01/12 Pfizer's Barrett named CEO of Novartis Oncology
01/11 AMGEN : European Medicines Agency Accepts Filing for EVENITY
01/09 UCB : European Medicines Agency Accepts Filing for EVENITYTM
2017 European stocks sink on Flynn guilty plea after choppy session
2017 European stocks sink on Flynn guilty plea after choppy session
2017 UCB : New study data shows prior osteoporotic fractures put women at increased r..
2017 DERMIRA : and UCB Agree to End Collaboration Agreement for CIMZIA
2017 UCB : Dermira and UCB Agree to End Collaboration Agreement for CIMZIA …
2017 UCB FIRST NINE MONTHS INTERIM REPORT :  Strong 9 …
2017 UCB : By the time you finish reading this headline another person …
2017UCB SA : quaterly earnings release
2017 UCB : Transparency notification The Capital Group Companies
2017 UCB : Transparency notification The Capital Group Companies
2017 NEW INDICATION FOR BRIVIACT® (BRIVAR : UCB’s newest antiepileptic drug &he..
2017 UCB : New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of..
More most relevant news
All news about UCB
01/19 UCB S.A. REPORTS FINDINGS IN PARKINS : A randomized,...
01/12 Pfizer's Barrett named CEO of Novartis Oncology
01/11 AMGEN : European Medicines Agency Accepts Filing for EVENITY
01/09 UCB : European Medicines Agency Accepts Filing for EVENITYTM
01/04 DATA ON PSORIATIC ARTHRITIS DISCUSSE : ...
2017 European stocks sink on Flynn guilty plea after choppy session
2017 European stocks sink on Flynn guilty plea after choppy session
2017 UCB : Research Conducted at UCB S.A. Has Provided New Information about Clinical..
2017 UCB : New study data shows prior osteoporotic fractures put women at increased r..
2017 DERMIRA : and UCB Agree to End Collaboration Agreement for CIMZIA
More news
Sector news : Pharmaceuticals - NEC
01/22 WILLIAM ACKMAN : Ackman cuts staff, shuns limelight as he seeks to turn around f..
01/22 Stocks hit record as senators reach deal to end shutdown
01/22 Canada's small financial firms get buzz from weed stocks
01/22 Big Drugmakers Pay Big Prices for Promising Biotechs
01/22 Dealmaking drives European stocks as equity melt-up continues
01/22 UK stocks decline as gamblers stumble on government clampdown worries
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/19 Potential suitors eyeing Acorda Therapeutics, shares ahead 9% premarket
01/08 EMA accepts UCB's marketing application for osteoporosis med romosozumab
2017 Dermira to returns rights to psoriasis candidate Cimzia back to UCB; shares d..
2017 UCB's (UCBJF) CEO Jean Tellier on Q2 2017 Results - Earnings Call Transcript
2017 FDA rejects Amgen's marketing application for osteoporosis candidate romosozu..
Latest Tweets
01/22Acorda Rumored to be Gaining Buyout Interest From Biogen, UCB and Other Suito.. 
01/19Improv is labor. So why doesn't UCB pay its performers?
4
01/19Biogen, UCB step up to kick the tires at Acorda as buyout buzz grows — report.. 
01/19Jefferies Group Sets UCB FY2017 Earnings Estimates at $5.23 EPS.  
01/19Biogen, UCB step up to kick the tires at Acorda as buyout buzz grows — report..
8
More tweets
Qtime:58
Financials (€)
Sales 2017 4 394 M
EBIT 2017 1 019 M
Net income 2017 667 M
Debt 2017 516 M
Yield 2017 1,77%
P/E ratio 2017 19,20
P/E ratio 2018 16,96
EV / Sales 2017 3,22x
EV / Sales 2018 2,99x
Capitalization 13 615 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 67,1 €
Spread / Average Target -4,1%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB5.77%16 637
JOHNSON & JOHNSON5.47%395 886
NOVARTIS1.19%227 592
PFIZER1.99%220 189
ROCHE HOLDING LTD.-4.87%211 135
MERCK AND COMPANY8.90%167 132